Q3 25 EPS
$-0.11
BEAT +37.25%
Est. $-0.18
Q3 25 Revenue
$334.2M
BEAT +1.68%
Est. $328.7M
vs S&P Since Q3 25
-36.9%
TRAILING MARKET
TEM -29.3% vs S&P +7.6%
Market Reaction
Did TEM Beat Earnings? Q3 2025 Results
Tempus AI delivered a convincing beat across the board in Q3 2025, posting a non-GAAP loss of $0.11 per share against a consensus estimate of $0.18, a 37.25% positive surprise, while revenue climbed 84.7% year-over-year to $334.21 million, edging pas… Read more Tempus AI delivered a convincing beat across the board in Q3 2025, posting a non-GAAP loss of $0.11 per share against a consensus estimate of $0.18, a 37.25% positive surprise, while revenue climbed 84.7% year-over-year to $334.21 million, edging past the $328.67 million Wall Street expected. The primary engine behind that growth was the Genomics segment, which more than doubled to $252.88 million, propelled by the integration of Ambry Genetics and accelerating oncology testing volumes that reached 217,000 clinical tests in the quarter. Perhaps the quarter's most significant milestone was achieving positive Adjusted EBITDA of $1.48 million, a $23.30 million swing from the prior-year loss, signaling that the company's rapid scaling is beginning to generate real operating leverage. Investors weighing what comes next will note that management raised full-year 2025 revenue guidance to approximately $1.27 billion, representing roughly 80% annual growth, while guiding Q4 Adjusted EBITDA to approximately $20 million despite the Paige acquisition adding around $5 million in quarterly losses.
Key Takeaways
- • 84.7% year-over-year revenue growth driven by Genomics segment doubling
- • 217,000 clinical tests delivered, 33% YoY volume growth with Oncology volume accelerating to 27% and Hereditary at 37%
- • Insights data licensing bookings of $150 million across multiple new contracts with 37.6% YoY revenue growth
- • Gross margin expansion to 62.8% from 58.5% year-over-year
- • Achieved positive Adjusted EBITDA of $1.5 million, a $23.3 million improvement year-over-year
TEM YoY Financials
Q3 2025 vs Q3 2024, source: SEC Filings
TEM Revenue by Segment
With YoY comparisons, source: SEC Filings
“Not only are we growing at an incredible rate, reaching positive adjusted EBITDA marks an important milestone and reflects the strength of our underlying business.”
— Eric Lefkofsky, Q3 2025 Earnings Press Release
TEM Earnings Trends
TEM vs Market 30 Day Price Reactions
30-day stock return vs benchmark after each earnings
TEM EPS Trend
Earnings per share: estimate vs actual
TEM Revenue Trend
Quarterly revenue: estimate vs actual
TEM Quarterly Results
5 quarters of earnings data
| Quarter | EPS Est. | EPS Act. | Surprise | Revenue | Rev. Surprise |
|---|---|---|---|---|---|
| Q1 26 BEAT | $-0.20 | $-0.13 | +35.36% | $348.1M | +0.78% |
| Q4 25 BEAT FY | $-0.05 | $-0.04 | +22.03% | $367.2M | +1.05% |
| FY Full Year | — | $-0.61 | — | $1.27B | — |
| Q3 25 BEAT | $-0.18 | $-0.11 | +37.25% | $334.2M | +1.68% |
| Q2 25 BEAT | $-0.25 | $-0.25 | +1.15% | $314.6M | +5.67% |
| Q1 25 BEAT | $-0.27 | $-0.24 | +10.21% | $255.7M | +3.07% |